Baseline demographics and clinical characteristics of 69 patients with eosinophilic granulomatosis with polyangiitis treated with rituximab
| Sex Female/Male | 44/25 |
| Age at first rituximab, median (IQR) | 51 (39.5–58.0) |
| ANCA status (historical or at treatment onset), no of patients (%) | |
| Positive (including immunofluorescence) | 24 (34.8) |
| Negative (including immunofluorescence) | 45 (65.2) |
| Positive C-or P-ANCA (only immunofluorescence) | 20 (29.0) |
| PR3-ANCA | 9 (13.0) |
| MPO-ANCA | 16 (23.2) |
| No of prior immunosuppressive therapies: mean±SD; median (IQR) | 2.37±1.46; 2 (1–3) |
| Immunosuppressive drugs prior to rituximab, no of patients (%) | |
| Cyclophosphamide | 34 (49.3) |
| Azathioprine | 46 (66.7) |
| Mycophenolate mofetil | 39 (56.5) |
| Methotrexate | 17 (24.6) |
| Intravenous immunoglobulin | 11 (15.9) |
| Alemtuzumab | 3 (4.3) |
| Etanercept | 1 (1.4) |
| Infliximab | 2 (2.9) |
| Mepolizumab | 1 (1.4) |
| Omalizumab | 1 (1.4) |
| No previous immunosuppressive treatment | 4 (5.8) |
| DEI score at first rituximab treatment, mean±SD | 6±3.1 |
| BVAS at first rituximab, mean±SD; median (IQR) | 7.05 (±5.22); 6.0 (3.0–8.5) |
| Organ involvement according to DEI, no of patients (%) | |
| Lung (including asthma) | 68 (98.6) |
| Ear, nose and throat (ENT) | 61 (88.4) |
| Arthralgia/arthritis | 32 (46.4) |
| Skin | 41 (59.4) |
| Peripheral nervous system | 40 (58.0) |
| Renal | 11 (15.9) |
| Gastrointestinal tract (including biliary system) | 12 (17.4) |
| Heart | 15 (21.7) |
| Eyes | 8 (11.6) |
| Central nervous system | 3 (4.3) |
| Urogenital tract | 2 (2.9) |
| Refractory asthma | 46 (66.6) |
| Refractory ENT disease | 23 (33.3) |
ANCA, anti-neutrophil cytoplasmic antibodies; BVAS, Birmingham Vasculitis Activity Score; DEI, Disease Extent Index; MPO, myeloperoxidase; PR3, proteinase-3.